Omeprazole treatment does not affect the metabolism of caffeine.
暂无分享,去创建一个
R. Bergstrand | P. Lagerström | S. Eriksson | P O Lagerström | I Skånberg | R Bergstrand | T Andersson | C Cederberg | S Eriksson | I. Skånberg | C. Cederberg | T. Andersson
[1] J. Miners,et al. Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies. , 1988, Biochemical pharmacology.
[2] A. Richens,et al. Oral phenytoin pharmacokinetics during omeprazole therapy. , 1987, British journal of clinical pharmacology.
[3] S. Spielberg,et al. A urinary metabolite ratio that reflects systemic caffeine clearance , 1987, Clinical pharmacology and therapeutics.
[4] G. Porro,et al. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. , 1986, Journal of clinical gastroenterology.
[5] J. Bridges,et al. The relationship between the binding of 2-n-alkylbenzimidazoles to rat hepatic microsomal cytochrome P-450 and the inhibition of monooxygenation. , 1982, Biochemical pharmacology.
[6] T. Leemann,et al. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers , 2004, European Journal of Clinical Pharmacology.
[7] R. Branch,et al. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities , 1989, Clinical pharmacology and therapeutics.
[8] F. Gonzalez,et al. The molecular biology of cytochrome P450s. , 1988, Pharmacological reviews.
[9] R. Gugler,et al. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. , 1985, Gastroenterology.
[10] M. Butler,et al. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[11] J. Dent,et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. , 1988, Gastroenterology.
[12] P. Watkins,et al. Distribution of cytochromes P-450, cytochrome b5, and NADPH-cytochrome P-450 reductase in an entire human liver. , 1990, Biochemical pharmacology.
[13] M. J. Coon,et al. The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. , 1989, DNA.
[14] M. Classen,et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. , 1989, The New England journal of medicine.
[15] A. Boobis,et al. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. , 1990, British journal of clinical pharmacology.
[16] V. Marks,et al. Determination of the urinary metabolites of caffeine and theophylline by high-performance liquid chromatography. A comparative study of a direct injection and an ion-pair extraction procedure. , 1986, Journal of chromatography.
[17] S. Devenish-Meares,et al. Propranolol steady-state pharmacokinetics are unaltered by omeprazole , 2004, European Journal of Clinical Pharmacology.
[18] R. Edwards,et al. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. , 1988, British journal of clinical pharmacology.
[19] H. Larsson,et al. The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro. , 1985, Scandinavian journal of gastroenterology. Supplement.
[20] L. Bertilsson,et al. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype , 1989, Clinical pharmacology and therapeutics.
[21] S. Loft,et al. Cytochrome P450 IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise. , 1991, Advances in experimental medicine and biology.
[22] U. Haglund,et al. Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man. , 1983, Gut.
[23] K. Brøsen,et al. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. , 1989, British journal of clinical pharmacology.
[24] B K Tang,et al. Variability in caffeine metabolism , 1983, Clinical pharmacology and therapeutics.
[25] P. Maurel,et al. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. , 1990, Gastroenterology.
[26] K. Anderson,et al. Enhanced phenacetin metabolism in human subjects fed charcoal‐broiled beef , 1976, Clinical pharmacology and therapeutics.
[27] G. Tucker,et al. Oxidation phenotype--a major determinant of metoprolol metabolism and response. , 1982, The New England journal of medicine.
[28] J. Miners,et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. , 1991, British journal of clinical pharmacology.
[29] D. Grant,et al. Effect of allopurinol on caffeine disposition in man. , 1986, British journal of clinical pharmacology.
[30] P. Lagerström,et al. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. , 1984, Journal of chromatography.
[31] R. Gugler,et al. Omeprazole inhibits oxidative drug metabolism , 1985 .
[32] L. Bertilsson,et al. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. , 1990, Therapeutic drug monitoring.
[33] T. Andersson,et al. A Study of the Interaction Between Omeprazole and Phenytoin in Epileptic Patients , 1990, Therapeutic drug monitoring.
[34] R. Gugler,et al. Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. , 1987, Pharmacology & therapeutics.